Abstract
454P A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have